Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
https://seekingalpha.com/news/4089446-needham-sees-bsx-cnmd-rmd-beating-street-despite-medtech-slow-down?source=feed_sector_healthcare
Apr 14, 2024 - Needham estimates Q1 medtech sales grew less than expected, but that Boston Scientific, CONMED, ResMed and Surmodics should still be able to beat the Street. Read more here.
0
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
https://www.zacks.com/stock/news/2256177/what-s-in-store-for-boston-scientific-bsx-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2256177
Apr 16, 2024 - Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
0
Unveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2258362/unveiling-boston-scientific-bsx-q1-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2258362
Apr 19, 2024 - Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
0
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
https://www.zacks.com/stock/news/2260506/what-s-in-store-for-these-4-medical-products-stocks-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2260506
Apr 23, 2024 - Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
0
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
https://www.zacks.com/stock/news/2261543/boston-scientific-bsx-q1-earnings-beat-estimates-view-raised?cid=CS-ZC-FT-analyst_blog|earnings_article-2261543
Apr 24, 2024 - Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
0
3 Medical Products Stocks Set to Beat This Earnings Season
https://www.zacks.com/stock/news/2263462/3-medical-products-stocks-set-to-beat-this-earnings-season?cid=CS-ZC-FT-earnings_esp-2263462
Apr 26, 2024 - Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
0
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
https://www.zacks.com/stock/news/2267265/reasons-to-retain-quest-diagnostics-dgx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2267265
May 02, 2024 - Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
0
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
https://www.zacks.com/stock/news/2268227/hologic-s-holx-q2-earnings-beat-estimates-2024-view-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2268227
May 03, 2024 - Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
0
Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up
https://www.zacks.com/stock/news/2270706/masimo-masi-q1-earnings-beat-estimates-24-eps-view-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2270706
May 08, 2024 - Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.
0
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
https://www.zacks.com/stock/news/2270793/nevro-s-nvro-q1-earnings-and-sales-beat-estimates-margins-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2270793
May 08, 2024 - Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
0
Page 1>